A strict new vaccine approval process in the U.S. could dramatically slow things down for biopharma and the public, experts ...

AstraZeneca was involved in one of the standout I&I deals of 2025 as it entered into a global strategic collaboration with Harbour BioMed in March that involved an upfront payment, near-term milestone ...

Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.

BIO-Europe Startup Spotlight returns to Lisbon in March 2026, showcasing Europe’s top early-stage biotech pitches to industry ...

Discover top biotech companies for 2026, featuring emerging stars and leaders set for major clinical and regulatory ...

Discover what the next wave of AI-assisted drug discovery looks like and how it can help biotech - the AI and physics combo.

Ghent is boosting its biopharma hub with cutting-edge infrastructure, world-class research, and a thriving life sciences ...

An end-of-the-year slowdown has not been witnessed by the biopharma industry yet, and certainly not in the biotech deals ...

The companies Cogent Biosciences, Braveheart Bio, and AAVantgarde bagged the biggest biotech funding rounds overall in November 2025.

News & press releases monitoring: We closely monitor the latest news and press releases, ensuring we only feature investments that could have a real impact on the industry. Specialized databases: We ...

A deficiency of dopamine: how does Parkinson’s disease affect the body? Unlike levodopa, which, when it reaches the brain gets converted to dopamine, the drug in question, tavapadon, activates ...